To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
CHHIP stands for Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer, a treatment protocol currently undergoing clinical trials for the treatment of prostate cancer using external beam radiotherapy.
Additional recommended knowledge
The main arm of the protocol prescribes 74 Gy to the prostate, with optional additional volumes around the prostate (such as the seminal vesicles and nodes prescribed to 71 Gy and 59 Gy. Each target with a prescribed dose must receive at least 95% of that dose to at least 99% of its volume and the dose to the 'hottest' 1% of the volume must be recorded. There are various limits on doses delivered to healthy tissues:
Rectal dose constraints:
Femoral head constraints:
The protocol has three arms, comparing conventional 2-Gray-per-fraction treatments against hypofractionated 3-Gray-per-fraction. One arm of the trial is the control group, receiving the standard 74 Gy in 37 fractions. The second arm prescribes 60 Gy in 20 fractions and the third prescribes 57 Gy in 19 fractions. The dose constraints for the hypofractionated arms of the trial are dose-scaled equivalents of those determined for the 74 Gy arm.
Inclusion Criteria a) Histologically confirmed, previously untreated locally confined adenocarcinoma of the prostate b) All clinical T categories
Exclusion criteria a) Patients with T3 cancers with Gleason Sum=8 cancers are ineligible b) Prior pelvic radiotherapy or radical prostatectomy c) Previous androgen deprivation d) Life expectancy <10 years e) Previous active malignancy within the last five years other than basal cell carcinoma f) Co-morbid conditions likely to impact on the advisability of radical radiotherapy (e.g. previously inflammatory bowel disease, previous colorectal surgery, significant bladder instability or urinary incontinence) g) Full anticoagulation with e.g. Warfarin or Heparin h) Hip prosthesis or fixation which would interfere with standard radiation beam configuration
The trial is being run and co-ordinated by Prof David Dearnaley at the Institute of cancer Research, Surrey.
The trial aims to recruit over 2162 patients. As of May 2007, 671 patients had been recruited onto the trial, an accrual of 30%. The trial will close in 2015.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "CHHIP". A list of authors is available in Wikipedia.|